| Vedolizumab as induction and maintenance therapy for ulcerative colitis BG Feagan, P Rutgeerts, BE Sands, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 699-710, 2013 | 2584 | 2013 |
| The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases D Soler, T Chapman, LL Yang, T Wyant, R Egan, ER Fedyk Journal of Pharmacology and Experimental Therapeutics 330 (3), 864-875, 2009 | 535 | 2009 |
| An overview of the mechanism of action of the monoclonal antibody vedolizumab T Wyant, E Fedyk, B Abhyankar Journal of Crohn's and Colitis 10 (12), 1437-1444, 2016 | 283 | 2016 |
| Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease M Rosario, NL Dirks, MR Gastonguay, AA Fasanmade, T Wyant, A Parikh, ... Alimentary pharmacology & therapeutics 42 (2), 188-202, 2015 | 246 | 2015 |
| Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study A Parikh, T Leach, T Wyant, C Scholz, S Sankoh, DR Mould, T Ponich, ... Inflammatory bowel diseases 18 (8), 1470-1479, 2012 | 241 | 2012 |
| Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results T Wyant, T Leach, S Sankoh, Y Wang, J Paolino, MF Pasetti, BG Feagan, ... Gut 64 (1), 77-83, 2015 | 197 | 2015 |
| Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte … J Gilbert, J Lekstrom-Himes, D Donaldson, Y Lee, M Hu, J Xu, T Wyant, ... The American journal of cardiology 107 (6), 906-911, 2011 | 183 | 2011 |
| A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab M Rosario, NL Dirks, C Milch, A Parikh, M Bargfrede, T Wyant, E Fedyk, ... Clinical pharmacokinetics 56, 1287-1301, 2017 | 162 | 2017 |
| Exclusive Antagonism of the α4β7 Integrin by Vedolizumab Confirms the Gut-selectivity of This Pathway in Primates ER Fedyk, T Wyant, LL Yang, V Csizmadia, K Burke, H Yang, VJ Kadambi Inflammatory bowel diseases 18 (11), 2107-2119, 2012 | 150 | 2012 |
| Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis MC Lebre, CE Vergunst, IYK Choi, S Aarrass, ASF Oliveira, T Wyant, ... PLoS One 6 (7), e21772, 2011 | 117 | 2011 |
| Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype C Milch, T Wyant, J Xu, A Parikh, W Kent, I Fox, J Berger Journal of neuroimmunology 264 (1-2), 123-126, 2013 | 102 | 2013 |
| Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis KG Haanstra, SO Hofman, DM Lopes Estêvão, ELA Blezer, J Bauer, ... The Journal of Immunology 190 (5), 1961-1973, 2013 | 91 | 2013 |
| MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double … CE Vergunst, DM Gerlag, L von Moltke, M Karol, T Wyant, X Chi, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009 | 78 | 2009 |
| In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes T Wyant, L Yang, E Fedyk MAbs 5 (6), 842-850, 2013 | 61 | 2013 |
| 943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial BG Feagan, PJ Rutgeerts, BE Sands, J Colombel, WJ Sandborn, ... Gastroenterology 5 (142), S-160-S-161, 2012 | 49 | 2012 |
| Autoantibodies to band 3 during aging and disease and aging interventions. MM Kay, T Wyant, J Goodman Annals of the New York Academy of Sciences 719, 419-447, 1994 | 46 | 1994 |
| Fecal calprotectin responses following induction therapy with vedolizumab in moderate to severe ulcerative colitis: a post hoc analysis of GEMINI 1 W Reinisch, B Bressler, R Curtis, A Parikh, H Yang, M Rosario, A Røseth, ... Inflammatory bowel diseases 25 (4), 803-810, 2019 | 37 | 2019 |
| Phase I study of the investigational anti-guanylyl cyclase antibody–drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies K Almhanna, T Kalebic, C Cruz, JE Faris, DP Ryan, JA Jung, T Wyant, ... Clinical Cancer Research 22 (20), 5049-5057, 2016 | 32 | 2016 |
| Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic … SF Jones, RB Cohen, JC Bendell, CS Denlinger, RD Harvey, ... Journal of Clinical Oncology 28 (15_suppl), 3081-3081, 2010 | 30 | 2010 |
| Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab T Wyant, J Estevam, L Yang, M Rosario Cytometry Part B: Clinical Cytometry 90 (2), 168-176, 2016 | 28 | 2016 |
